Provention Bio Inc PRVB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:36 PM EST
9.26quote price arrow up+0.16 (+1.76%)
Volume
781,635
52 week range
3.18 - 10.88
Loading...
  • Open9.00
  • Day High9.36
  • Day Low8.95
  • Prev Close9.10
  • 52 Week High10.88
  • 52 Week High Date01/03/23
  • 52 Week Low3.18
  • 52 Week Low Date07/05/22

Key Stats

  • Market Cap807.386M
  • Shares Out87.19M
  • 10 Day Average Volume0.82M
  • Dividend-
  • Dividend Yield-
  • Beta2.21
  • YTD % Change-12.68

KEY STATS

  • Open9.00
  • Day High9.36
  • Day Low8.95
  • Prev Close9.10
  • 52 Week High10.88
  • 52 Week High Date01/03/23
  • 52 Week Low3.18
  • 52 Week Low Date07/05/22
  • Market Cap807.386M
  • Shares Out87.19M
  • 10 Day Average Volume0.82M
  • Dividend-
  • Dividend Yield-
  • Beta2.21
  • YTD % Change-12.68

RATIOS/PROFITABILITY

  • EPS (TTM)-1.56
  • P/E (TTM)-5.95
  • Fwd P/E (NTM)-4.35
  • EBITDA (TTM)-113.221M
  • ROE (TTM)-76.10%
  • Revenue (TTM)2.799M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,791.21%
  • Debt To Equity (MRQ)16.09%

EVENTS

  • Earnings Date02/22/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Provention Bio Inc

 

Content From Our Affiliates

Profile

MORE
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on intercepting and preventing immune-mediated diseases. The Company's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule...
Wayne Pisano
Independent Chairman of the Board
Ashleigh Palmer
President, Chief Executive Officer, Co-Founder, Director
Christina Yi
Chief Operations Officer
Thierry Chauche
Chief Financial Officer
Address
55 BROAD STREET, 2ND FLOOR
Red Bank, NJ
07701
United States

Top Peers

SYMBOLLASTCHG%CHG
DYN
Dyne Therapeutics Inc
13.98-0.15-1.06%
PNT
POINT Biopharma Global Inc
8.00-0.10-1.30%
RAPT
Rapt Therapeutics Inc
27.93-0.33-1.17%
FDMT
4D Molecular Therapeutics Inc
22.37-0.68-2.95%
EWTX
Edgewise Therapeutics Inc
10.75-0.05-0.46%